|Videos|December 6, 2019
Andrew Russman, DO: Importance of Controlled Blood Pressure
Author(s)Andrew Russman, DO
The medical director of the Comprehensive Stroke Center at Cleveland Clinic detailed the advantages of controlling blood pressure.
Advertisement
“Intensive blood pressure management is a much better approach for long term reduction for stroke and other cardiovascular events.”
An increased rate of blood pressure can not only raise the risk of cardiovascular events but put patients in danger for other diseases caused by uncontrolled hypertension. Clinicians treating stroke, such as Andrew Russman, DO, medical director, Comprehensive Stroke Center, Cleveland Clinic, believe that 120 over 80 is the ideal blood pressure to avoid cardiovascular events such as stroke.
Patients have a tendency to shy away from being as aggressive to lower their blood pressure because of the adverse effects that may come with this practice—this overly aggressive effort can lead to complications such as ischemia buildup in the brain over time. Although, Russman believes the benefits of having lowered blood pressure outweigh the complications that come with it.
Additionally, high blood pressure comes with a slew of adverse effects on its own, leading to uncontrolled hypertension, which can cause additional strain on the heart, leaving organ damage and increasing the risk of other events such as renal disease, eye diseases, and brain diseases. In an interview with NeurologyLive, Russman discusses why keeping blood pressure at a lower, more normal level is beneficial, especially for the long-term future of patients.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
5